Making millions in the market is possible. But only with conviction and a deep understanding of the company thesis.
Most people sold when $Hims & Hers Health Inc.(HIMS)$
Here’s what changed since the lows — and why I’m still allocating:
1. *De-risking:* $NVO partnership removes a major overhang
2. *Expansion:* Aggressive global M&A building the DTC engine
3. *Category tailwind:* Peptides are going mainstream, and $HIMS is positioned as the distribution layer
4. *Macro shift:* Fed likely turns dovish after President Trump nominated Kevin Warsh
5. *Geopolitics:* Iran war likely to end soon, backdrop turning friendlier
6. *Consumer boost:* Oil price tanking supports discretionary spending
7. *Sentiment setup:* Short interest at ∼30-35% of float
That last point matters. 30%+ short interest isn’t just bearishness — it’s stored energy. Shorts eventually become buyers. There’s a hard cap on how much of the float can be shorted, but no cap on covering pressure.
So we have: improving fundamentals + secular tailwind + distribution advantage + macro turning + crowded short.
That’s not a broken story. That’s a coiled spring.
I’ll keep stirring the pot 🍲
@TigerObserver @TigerClub @TigerStars @TigerPM @Daily_Discussion
Comments